Keith Marchiando - Zivo Bioscience Treasurer CFO
Insider
Keith Marchiando is Treasurer CFO of Zivo Bioscience
| Age | 61 |
| Phone | 248 452 9866 |
| Web | https://www.zivobioscience.com |
Zivo Bioscience Management Efficiency
The company has return on total asset (ROA) of (1.6474) % which means that it has lost $1.6474 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (39.5602) %, meaning that it created substantial loss on money invested by shareholders. Zivo Bioscience's management efficiency ratios could be used to measure how well Zivo Bioscience manages its routine affairs as well as how well it operates its assets and liabilities.Zivo Bioscience currently holds 445.18 K in liabilities with Debt to Equity (D/E) ratio of 0.28, which may suggest the company is not taking enough advantage from borrowing. Zivo Bioscience has a current ratio of 2.04, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Zivo Bioscience's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Denise Carter | Quoin Pharmaceuticals Ltd | 56 | |
| Evan Hecker | Ikena Oncology | N/A | |
| Petpiboon Prasit | Tempest Therapeutics | N/A | |
| Jeffrey Ecsedy | Ikena Oncology | 55 | |
| Deborah Knobelman | Senti Biosciences | 50 | |
| Angela Nelms | RenovoRx | 47 | |
| Gordon JD | Quoin Pharmaceuticals Ltd | 61 | |
| Wei MD | Erasca Inc | 54 | |
| Ramtin MD | RenovoRx | 59 | |
| Anne Moon | Tempest Therapeutics | N/A | |
| David MD | Erasca Inc | 41 | |
| Allan MD | Foghorn Therapeutics | 49 | |
| Daniel Schneiderman | Pasithea Therapeutics Corp | 47 | |
| CPA MS | Erasca Inc | 55 | |
| Fanny Cavalie | Foghorn Therapeutics | 46 | |
| Alfredo Castro | Ikena Oncology | N/A | |
| Tiago Marques | Pasithea Therapeutics Corp | 47 | |
| MBA MD | Ikena Oncology | 59 | |
| James Ahlers | RenovoRx | 60 | |
| Michael LaCascia | Foghorn Therapeutics | 59 | |
| Christopher Roenfeldt | Forte Biosciences | N/A | |
Management Performance
| Return On Equity | -39.56 | ||||
| Return On Asset | -1.65 |
Zivo Bioscience Leadership Team
Elected by the shareholders, the Zivo Bioscience's board of directors comprises two types of representatives: Zivo Bioscience inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Zivo. The board's role is to monitor Zivo Bioscience's management team and ensure that shareholders' interests are well served. Zivo Bioscience's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Zivo Bioscience's outside directors are responsible for providing unbiased perspectives on the board's policies.
| John Payne, Director | ||
| Keith Marchiando, Treasurer CFO |
Zivo Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Zivo Bioscience a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -39.56 | ||||
| Return On Asset | -1.65 | ||||
| Operating Margin | (133.25) % | ||||
| Current Valuation | 2.02 M | ||||
| Shares Outstanding | 1.82 M | ||||
| Shares Owned By Insiders | 25.23 % | ||||
| Shares Owned By Institutions | 4.44 % | ||||
| Number Of Shares Shorted | 35.47 K | ||||
| Price To Earning | (1.95) X | ||||
| Price To Book | 17.86 X |
Check out Your Current Watchlist to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as various price indices. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Other Consideration for investing in Zivo Stock
If you are still planning to invest in Zivo Bioscience check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Zivo Bioscience's history and understand the potential risks before investing.
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Commodity Directory Find actively traded commodities issued by global exchanges |